Avoiding the poverty traps from chronic disease
Rapid economic growth in Asia does not, per se, guarantee rapid improvements in health outcomes. Indeed, the health gaps between urban and rural areas and between poor and rich people are widening. It is easy for households to spend too well and not wisely on chronic disease care. Historical lessons from countries in the Organisation for Economic Cooperation and Development are clear: public financing of clinical services is essential to maintain costs and to ensure quality and equitable access. 8 Historically, China and India have spent far too little on health, partly because health has not been seen as a "productive" part of the economy 8 and also because of low national income. Income growth in China and India means that they are now able to spend more from the public purse.
• The rise of chronic diseases in South and East Asia (most importantly in China and India) has major health and poverty implications and presents a substantial challenge for governments • Of the 8 7 Third, despite the notion that these are "diseases of affluence," much of the burden of chronic disease and its risk factors are concentrated among the poor. For example, smoking prevalence among illiterate Chinese and Indian males is nearly 50% higher than among their literate counterparts. 9 Household tobacco use in India is associated with low birth weight and premature birth, as well as with economic hardship arising from increased hospital admissions. 10 Adult ill health is a major reason for households sliding into poverty.
11 Fourth, there is evidence that productive adult health has been central to economic growth in the region, partly through increases in savings rates, along with better productivity. 
Four cost-effective approaches to control chronic disease in Asia
As examples of highly practicable interventions that reach the poor and that reduce premature mortality, we consider 4 approaches, drawing on information gathered by the Disease Control Priorities Project. 
Tobacco control
In China and India, as in most low-income countries, death in middle age increases in relative importance as the effects of smoking increase. However, tobacco kills differently in different parts of South and East Asia. In China, the leading causes of death from smoking are chronic lung disease and lung cancer, with a noted excess also of tuberculosis deaths but much lower heart disease. 12 In India, the leading causes of death from smoking are tuberculosis and heart disease, with relatively less lung cancer. 13 Unless there is widespread cessation of smoking, some 100 million of China's 300 million male smokers and about 40 million of India's 100 million male smokers will eventually die from tobacco-related causes.
Many countries in the Organisation for Economic Cooperation and Development have seen substantial declines in smoking deaths over the past 2 decades; for example, lung cancer deaths among men 30-44 years of age have fallen by nearly 80% in the United Kingdom, 14,15 a change attributable chiefly to marked increases in cessation. Also, in the countries of the Organisation for Economic Co-operation and Development, more than 30% of the adult population are exsmokers, in contrast to only 2% in India, 9% in China and 15% in Thailand. 16 Thailand is far ahead of China and India, as it has had a much more comprehensive tobacco-control strategy. In China, smoking cessation has increased only since about 1998, when the first scientific reports that smoking was killing large numbers of Chinese people appeared in the popular press. 12 A considerable number of tobacco deaths over the next half century could be prevented by encouraging current smokers to quit smoking. Reducing the uptake of smoking by children will yield benefits chiefly in the second half of the 21st century.
14,15 Cost-effective measures to encourage cessation and reduce uptake include higher taxes, which are vastly underused in Asia. For example, bidis, the most commonly smoked form of tobacco in India, have historically had low taxation rates. Other effective measures include restrictions on public smoking, government support for quit-smoking clinics, better public information about *Avoidance of disability is also important. Mortality does not capture all illnesses, specifically missing neuropsychiatric and musculoskeletal diseases. However, the correlation of mortality with morbidity for most major diseases is quite strong. Moreover, it is important to note that measurement error in disability estimates is much greater than in mortality estimates and often exceeds the desired change in health outcomes. For example, a health policy planner may desire a 10% improvement in diabetes outcomes, but if measurement error exceeds 10% in the health outcome measure, the planner will not know if the intervention has worked. Since death is a clear and usually measurable event, restricting analyses to mortality should reduce measurement error in health policy-making. For more details, including estimates of disability-adjusted life years in the region, see reference 3. †Adapted, with permission of the World Bank Group, from Jha and Anderson. 3 Original data source: Lopez and associates. 4 ‡Newer data from direct epidemiologic studies suggest that deaths from AIDS may be a magnitude lower than the indirect estimates from the Global Burden of Disease study.
Commentary
Commentary smoking hazards, and prominent warning labels on cigarette and bidi packs and packaging.
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Hepatitis B vaccination
An estimated 0.4 million deaths from liver cancer occur each year in South and East Asia, many of these due to chronic infection from hepatitis B. Universal immunization with hepatitis B vaccine, which was implemented in China in 2002 but has not yet been undertaken in India, is highly cost-effective and could avert up to 90% of the estimated 1.5 million deaths from liver cancer that will otherwise occur among those born in the region in the year 2000.
17 For those who are already infected, however, vaccination will not help. Strategies are needed to reduce cofactors, such as exposure to aflatoxins (toxic compounds produced by certain strains of fungi, which can damage the liver) and alcohol.
Screening for and vaccination against cervical cancer
Nearly 150 000 women die from cervical cancer each year in South and East Asia, 4 and almost all of these deaths are caused by human papillomavirus. Vaccines for this viral infection have now been introduced in Western countries. Making these widely accessible at reasonable cost to adolescent girls would avert a very large proportion of future deaths from cervical cancer among young adult women. Ensuring that all adult women undergo at least one Papanicolaou test or human papillomavirus screening for early cervical cancerwith referral if the result is positive -would be an effective way to reach older women who will not benefit from the new vaccines.
17
Low-cost combination drug therapy for vascular disease
There is considerable evidence that simple combinations of cheap drugs can be highly effective in reducing mortality among the millions of adults in South and East Asia who already have some form of vascular disease or diabetes. 18 For example, among patients with a history of occlusive vascular disease such as stroke or heart attack, use of acetylsalicylic acid, a statin and an antihypertensive drug could reduce the annual risk of major recurrence by about two-thirds; the 10-year risk of death or readmission to hospital is about 50% if people go untreated but only 16% if they receive daily treatment with 3 or 4 drugs. All of these drugs are inexpensive and could easily be packaged into "polypills" or "generic risk pills" for widespread use.
19 Indeed, China's success in ensuring widely accessible tuberculosis therapy with several drugs serves as a model of how simple drug therapy for vascular disease could be introduced in the region.
The globalization of evidence
Rapid globalization of goods and services also means that unique opportunities are arising to enhance global knowledge about the control of chronic disease. Already, large-scale "mega" trials conducted in China have had major impact on clinical practice in the West, 20 and India's biotechnology sector and its generic drug manufacturers are booming. However, Western academic institutions and industry still enjoy a comparative advantage in research. If this advantage could be appropriately levered, global knowledge would surely advance.
Consider a practical example. High blood cholesterol is a major risk factor for heart disease worldwide. A previous prospective study in China showed that the positive relation between risk of heart disease and total cholesterol levels in the blood continues down to at least 3 mmol/L (i.e., well below the range generally studied in Western populations 21 ). These findings (suggested earlier by Rose in his classic paper of 1985
22
) have only recently widened our perspective on what might be regarded as "normal" in Western populations. Indeed, they have also affected the way in which lipid-lowering therapy is managed in high-risk patients. 23 Similarly, much of what we know about chronic disease will be greatly enhanced by better scientific research in epidemiological studies currently under way in China and India.
24,25 Moreover, we can learn much from a better understanding of how information about risks is created and then communicated to and used by the public. A reasonable analogy for chronic disease research today would be the status of diarrhea research about 40 years ago, when such research was fragmented and of low impact. Led by the efforts of Bangladeshi institutions and support from the World Health Organization and others, oral rehydration therapy and related efforts initiated worldwide have markedly reduced childhood deaths from diarrhea.
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Priority research will involve developing a better understanding of the relationships among "known" risk factors, such as smoking, blood pressure and blood lipids, but also a better understanding of the complex interactions of obesity, diabetes, urbanization and vascular disease. Large-scale studies might well lead to better therapeutics with global relevance. There is every reason to believe that a major Asian-led effort to improve health research and development for the control of chronic disease, with support from global research and development partners, could be similarly effective in saving lives and reducing poverty in the 21st century.
